Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
OncoLink Scientific Meetings Coverage / ASTRO / OncoLink at ASTRO 2007 / Patient Summaries
Carolyn Vachani, RN, MSN, AOCN
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 5, 2007
Scientific Session: Chest Wall Radiation Alone for Breast Cancer Patients With 1-3 Positive Lymph Nodes Treated by Mastectomy
It is currently known that post-mastectomy radiation to the chest wall and axillary/clavicular lymphatics reduces local recurrence and increases survival in patients with 4 or more positive lymph nodes or tumors larger than 5 cm. It is uncertain whether there would be any benefit to giving radiation to those with tumors smaller than 5 cm or with only 1-3 positive lymph nodes after mastectomy. This study compared mastectomy alone to mastectomy plus radiation to the chest wall only or radiation to the chest wall and clavicular area.
The 238 participants were women (ages 31-93) with primary tumors less than 5cm and 1-3 positive lymph nodes. 165 got no radiation, 73 did receive radiation (46 to the chest wall only and 27 to the chest wall & clavicular area, 15 of whom also received radiation to the axillary area). Ninety-three percent of the participants also got adjuvant therapy (35 had chemotherapy, 54 had hormonal therapy, and 133 got both).
At 10 years, the rate of local recurrence (in the area of the original mastectomy or lymph nodes) was 10.2% in the patients without radiation, while no patients developed local recurrence in the treatment group. Patients who received radiation had better disease-free survival (meaning they were alive with no sign of disease) at five years (96% vs. 85%) and at 10 years (96% vs. 75%). The improvements in local recurrence rates and disease-free survival became evident within two years following mastectomy and radiation.
Among patients who did not receive radiation, poor tumor grade was the only factor associated with an increased risk of local recurrence.
This study is clearly important in showing that patients who receive postmastectomy radiation are less likely to experience a local recurrence and have an improved disease-free survival. However, the question regarding the extent of radiation that is needed cannot be addressed here, given that no one in the radiation groups had local recurrences and the number of patients was quite small. It will be important to conduct a larger study to determine if the smaller radiation field is as effective as including the clavicular area. This smaller field could spare some women the increased risk of side effects such as lymphedema and neuropathy due to damage to the brachial nerves.
Partially funded by an unrestricted educational grant from Bristol-Myers Squibb.
Dr. Vapiwala discusses the public awareness of prostate cancer and the public support for the disease. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

